Pharmaceuticals News and Research

RSS
Tamandare Explorations is now Tonix Pharmaceuticals

Tamandare Explorations is now Tonix Pharmaceuticals

Alexion third quarter total revenues increase to $204.0 million

Alexion third quarter total revenues increase to $204.0 million

Ipsen, Syntaxin collaborate to develop new botulinum toxins

Ipsen, Syntaxin collaborate to develop new botulinum toxins

Immdal sells its subsidiary Newport to Ewopharma

Immdal sells its subsidiary Newport to Ewopharma

JHU, Eisai enter drug-discovery research collaboration for brain disorders

JHU, Eisai enter drug-discovery research collaboration for brain disorders

SAIC receives NIAID contract to develop biopharmaceutical products for infectious diseases

SAIC receives NIAID contract to develop biopharmaceutical products for infectious diseases

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Medication therapy management in interprofessional heath care

Medication therapy management in interprofessional heath care

U of M technology may help prolong lives of people with trauma, massive blood loss

U of M technology may help prolong lives of people with trauma, massive blood loss

Oral laquinimod shows promise against multiple sclerosis

Oral laquinimod shows promise against multiple sclerosis

SomaLogic, Novartis enter multi-year research agreement

SomaLogic, Novartis enter multi-year research agreement

King's researchers create traditional Chinese medicine database

King's researchers create traditional Chinese medicine database

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

With clock ticking, super committee weighs suggestions, battles doubts

With clock ticking, super committee weighs suggestions, battles doubts

Commercialization strategies for next-generation medicines

Commercialization strategies for next-generation medicines

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

HMS launches Initiative in Systems Pharmacology

HMS launches Initiative in Systems Pharmacology

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

FDA approves Oxford BioMedica's UshStat IND to treat Usher syndrome type 1B

TPP, University of Dundee sign collaboration agreement for drug development fund

TPP, University of Dundee sign collaboration agreement for drug development fund

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

Takeda commences TAK-875 Phase 3 clinical trial program for type 2 diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.